A long term, open label, randomised study in patients with type 2 diabetes, comparing the combination of rosiglitazone and either metformin or sulphonylurea with metformin plus sulphonylurea on cardiovascular endpoints and glycaemia.
Latest Information Update: 25 Jun 2023
At a glance
- Drugs Rosiglitazone (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms RECORD
- Sponsors GlaxoSmithKline; GSK
- 18 Oct 2009 Results presented at the 20th World Diabetes Congress (WDC).
- 05 Jun 2009 Results from the final planned analysis published in the Lancet.
- 05 Jun 2009 The combined primary endpoint of 'Cardiovascular hospitalisation' and 'Cardiovascular death' (includes myocardial infarction, congestive heart failure and stroke) has been met.